JP5361386B2 - マトリックスメタロプロテイナーゼ１１ワクチン - Google Patents

マトリックスメタロプロテイナーゼ１１ワクチン Download PDF

Info

Publication number
JP5361386B2
JP5361386B2 JP2008533917A JP2008533917A JP5361386B2 JP 5361386 B2 JP5361386 B2 JP 5361386B2 JP 2008533917 A JP2008533917 A JP 2008533917A JP 2008533917 A JP2008533917 A JP 2008533917A JP 5361386 B2 JP5361386 B2 JP 5361386B2
Authority
JP
Japan
Prior art keywords
mmp
encoding
vaccine
ltb
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008533917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009509553A5 (https=
JP2009509553A (ja
Inventor
アウリシツキオ，ルイージ
ラ・モニカ，ニコラ
チリベルト，ジエンナーロ
ラツザロ，ドメニコ
モーリ，フエデリカ
ペルツツイ，ダニエラ
Original Assignee
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ filed Critical イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ
Publication of JP2009509553A publication Critical patent/JP2009509553A/ja
Publication of JP2009509553A5 publication Critical patent/JP2009509553A5/ja
Application granted granted Critical
Publication of JP5361386B2 publication Critical patent/JP5361386B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6416—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2008533917A 2005-10-07 2006-10-03 マトリックスメタロプロテイナーゼ１１ワクチン Expired - Fee Related JP5361386B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72449805P 2005-10-07 2005-10-07
US60/724,498 2005-10-07
PCT/EP2006/009536 WO2007042169A2 (en) 2005-10-07 2006-10-03 Matrix metalloproteinase 11 vaccine

Publications (3)

Publication Number Publication Date
JP2009509553A JP2009509553A (ja) 2009-03-12
JP2009509553A5 JP2009509553A5 (https=) 2009-10-22
JP5361386B2 true JP5361386B2 (ja) 2013-12-04

Family

ID=37451271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008533917A Expired - Fee Related JP5361386B2 (ja) 2005-10-07 2006-10-03 マトリックスメタロプロテイナーゼ１１ワクチン

Country Status (9)

Country Link
US (2) US8106176B2 (https=)
EP (1) EP1934246B8 (https=)
JP (1) JP5361386B2 (https=)
CN (1) CN101365715B (https=)
AT (1) ATE521629T1 (https=)
AU (1) AU2006301582B2 (https=)
CA (1) CA2623531C (https=)
ES (1) ES2370040T3 (https=)
WO (1) WO2007042169A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
EP2568044B1 (en) * 2008-09-29 2015-04-08 The Trustees of The University of Pennsylvania Tumor vascular marker-targeted vaccines
KR20120049214A (ko) 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 발열성 지방세포를 증가시키는 방법
AU2010282361B2 (en) * 2009-08-13 2015-03-19 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
CN107028886A (zh) 2009-11-04 2017-08-11 不列颠哥伦比亚大学 含有核酸的脂质粒子及相关的方法
WO2013059922A1 (en) 2011-10-25 2013-05-02 The University Of British Columbia Limit size lipid nanoparticles and related methods
CN105143456A (zh) 2013-03-15 2015-12-09 不列颠哥伦比亚大学 用于转染的脂质纳米粒子和相关方法
LT3388075T (lt) 2015-03-27 2023-11-10 Immatics Biotechnologies Gmbh Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš įvairius navikus (seq id 25 - mrax5-003)
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
CN110418648B (zh) * 2017-02-22 2023-09-08 丁恩雨 一种编码人GM-CSF与多串连表位融合的mRNA癌症疫苗
US20220362402A1 (en) * 2019-10-08 2022-11-17 Exhaura, Ltd. Compositions and methods for ocular therapy
US20240199725A1 (en) 2021-04-16 2024-06-20 Korea University Research And Business Foundation Human antibody targeting covid-19 virus
GB202117583D0 (en) * 2021-12-06 2022-01-19 Cambridge Entpr Ltd Protein expression
CN116590263A (zh) * 2023-07-02 2023-08-15 广州庆毅生物医药科技有限公司 一种重组蛋白、单克隆抗体及其检测试剂盒和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
GB9112553D0 (en) 1991-06-11 1991-07-31 Wellcome Found Fusion proteins
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
NZ332954A (en) * 1996-05-23 2000-07-28 Xoma Corp Use of BPI protein products to treat humans with hemorrhage due to trauma
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
BR0010077A (pt) 1999-04-26 2002-01-15 K U Leuven Res & Dev Universit Gene sintético para expressão de uma proteìna retroviral ativa em eucariotas
CA2385172A1 (en) * 1999-10-08 2001-04-19 Active Biotech Ab Ab5 toxin b subunit mutants with altered chemical conjugation characteristics
GB9930768D0 (en) * 1999-12-29 2000-02-16 Pfizer Ltd Composition
JP2004508064A (ja) 2000-09-15 2004-03-18 メルク　エンド　カムパニー　インコーポレーテッド コドン最適化ｈｉｖ１−ｇａｇ、ｐｏｌ、ｎｅｆおよび修飾体を発現する増強された第１世代アデノウイルスワクチン
US20040110152A1 (en) 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of matrix metalloproteinase 11 expression
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
EA012066B1 (ru) * 2003-10-10 2009-08-28 Паудерджект Вэксинс, Инк. Способ, вызывающий т-клеточный ответ
CA2555013C (en) * 2004-02-11 2013-10-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Carcinoembryonic antigen fusions and uses thereof

Also Published As

Publication number Publication date
ATE521629T1 (de) 2011-09-15
ES2370040T3 (es) 2011-12-12
EP1934246A2 (en) 2008-06-25
CN101365715B (zh) 2013-03-27
AU2006301582B2 (en) 2011-10-13
WO2007042169A3 (en) 2007-05-31
US8106176B2 (en) 2012-01-31
US20120177679A1 (en) 2012-07-12
US8492522B2 (en) 2013-07-23
CA2623531C (en) 2013-12-10
CA2623531A1 (en) 2007-04-19
JP2009509553A (ja) 2009-03-12
CN101365715A (zh) 2009-02-11
EP1934246B8 (en) 2012-02-08
US20090155298A1 (en) 2009-06-18
EP1934246B1 (en) 2011-08-24
WO2007042169A2 (en) 2007-04-19
AU2006301582A1 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
US8492522B2 (en) Matrix metalloproteinase 11 vaccine
AU2022200016B2 (en) Cancer vaccines and methods of treatment using the same
DK2155243T3 (en) Compositions and methods comprising KLK3, PSCA, or antigen FOLH1
US7446185B2 (en) Her2/neu target antigen and use of same to stimulate an immune response
EP2260862B1 (en) Compositions and methods for treating tumors presenting survivin antigens
KR20050010040A (ko) 면역원성 조성물
JP2010532656A (ja) 癌退縮抗原ｎｙ−ｅｓｏ−１およびｌａｇｅ−１を含む融合タンパク質
KR20090092271A (ko) 종양-관련 대식세포에 대한 면역 반응을 유발하기 위한 ｄｎａ 조성물
KR102158923B1 (ko) 암 백신
NZ543922A (en) Synthetic gene encoding human carcinoembryonic antigen and uses thereof
US20020177547A1 (en) Pharmaceutical compositions for treating or preventing cancer
HK40071546A (en) Cancer vaccines and methods of treatment using the same
EP1373505A2 (en) Tri-hybrid melanoma antigen
MXPA06009202A (en) Carcinoembryonic antigen fusions proteins and uses thereof
AU2002244196A1 (en) Tri-hybrid melanoma antigen
ZA200508013B (en) Synthetic gene encoding human carcinoembryonic antigen and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120110

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20120209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120404

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120411

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120518

RD07 Notification of extinguishment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7427

Effective date: 20120608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120706

RD07 Notification of extinguishment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7427

Effective date: 20120727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130424

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130724

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130820

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130903

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees